Why the study?
Preclinical studies suggest that type 2 immunity-related cytokines and cell types affect cardiac functions after myocardial infarction, but their roles and prognostic potential required review.
This review highlights the emerging role of type 2 immunity in cardiac healing and remodeling after myocardial infarction, suggesting potential therapeutic and prognostic applications.
May inform post-MI biomarker research; leaves open whether targeting type 2 immunity improves outcomes.
Type 2 immunity participates in the pathogeneses of helminth infection and allergic diseases. Emerging evidence indicates that the components of type 2 immunity are also involved in maintaining metabolic hemostasis and facilitating the healing process after tissue injury. Numerous preclinical studies have suggested regulation of type 2 immunity-related cytokines, such as interleukin-4, -13, and -33, and cell types, such as M2 macrophages, mast cells, and eosinophils, affects cardiac functions after myocardial infarction (MI), providing new insights into the importance of immune modulation in the infarcted heart. This review provides an overview of the functions of these cytokines and cells in the setting of MI as well as their potential to predict the severity and prognosis of MI.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: